Ipsen, a global biopharmaceutical company, is primarily owned by a combination of key family shareholders and institutional investors.
The most significant ownership stakes are held by members of the Beaufour family, specifically Henri Beaufour and Anne Beaufour, who each hold substantial percentages of the company's equities. Beyond these foundational family holdings, other notable shareholders include investment management firms and additional family interests.
Ipsen's Principal Shareholders
The ownership structure of Ipsen highlights a concentrated holding by its founding family alongside notable institutional and family investors. Below is a breakdown of the major shareholders:
| Shareholder | Percentage (%) | Equities Owned |
|---|---|---|
| Henri Beaufour | 26.03% | 21,816,679 |
| Anne Beaufour | 26.03% | 21,816,679 |
| Parvus Asset Management Europe Ltd. | 7.900% | 6,621,318 |
| Schwabe Family | 4.339% | 3,636,455 |
This structure indicates that while the Beaufour family maintains a controlling interest, a significant portion of the company is also held by institutional investors like Parvus Asset Management Europe Ltd., and other family entities such as the Schwabe Family. These diverse ownership stakes reflect a blend of long-term strategic family control and market-driven investment.
